Partner Scott Grzenczyk will speak on an ABA panel titled “Class Certification in Pharmaceutical Antitrust Litigation.” The event will be held on Monday, July 31.
Panelists will provide class certification decisions impacting both direct and indirect purchasers (end-payors). In particular, they will discuss the recent In re Niaspan Antitrust Litigation (3d Cir.) decision relating to end-payor ascertainability, and the In re Zetia Antitrust Litigation (4th Cir.) decision relating to direct purchaser numerosity.
Scott is a member of the ABA’s Antitrust Section and often contributes content for ABA publications.
For more information about the event, click here
